Albumin use in patients with cirrhosis is currently recommended for the treatment or prevention of conditions characterized by an acute worsening of effective volemia: its well-established indications are the prevention of paracentesis-induced circulatory dysfunction (PICD), of renal dysfunction induced by SBP, and the diagnosis and treatments of HRS in association with vasoconstrictors [4,32]. The gene discussed is ALB; the disease is Cirrhosis.